February 5, 2016 : Episode 1

Video

FDA Approval in Liposarcoma, Breakthrough Designations in mCRPC and AML, and More

Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
Bertram Yuh, MD, MISM, MSHCPM
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
Related Content
Bradley C. Carthon, MD, PhD
October 30th 2024

Patients Characteristics, Sequencing Considerations Are Vital in Prostate Cancer Management

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Maurie Markman, MD, of City of Hope
October 30th 2024

Precision Medicine Unfolds in Oncology, Bearing Substantial Implications for the Future

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

FDA
October 29th 2024

FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Ph+ Chronic-Phase Chronic Myeloid Leukemia

Harout Semerjian, CEO of GlycoMimetics
October 29th 2024

Uproleselan Plus Chemotherapy Fails to Improve EFS in Older Patients With AML